Pseudothrombocytopenia in a patient with bipolar type 2 disorder on lurasidone: A case report.
作者信息
Sakhardande Kasturi Atmaram, Sharma Lavanya P, Arumugham Shyam Sundar
机构信息
Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India. E-mail:
出版信息
Indian J Psychiatry. 2022 Jan-Feb;64(1):109-110. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_625_21. Epub 2022 Jan 21.
Abstract
摘要
相似文献
1
Pseudothrombocytopenia in a patient with bipolar type 2 disorder on lurasidone: A case report.
Indian J Psychiatry. 2022 Jan-Feb;64(1):109-110. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_625_21. Epub 2022 Jan 21.
2
Lurasidone-Induced Manic Switch in an Adolescent with Bipolar I Disorder: a Case Report.
East Asian Arch Psychiatry. 2021 Sep;31(3):81-83. doi: 10.12809/eaap2040.
3
Lurasidone in Therapy of Treatment-resistant Ultra-rapid Cycling Bipolar Disorder: Case Report.
Clin Psychopharmacol Neurosci. 2021 Aug 31;19(3):568-571. doi: 10.9758/cpn.2021.19.3.568.
4
Hospitalization risk among adults with bipolar I disorder treated with lurasidone versus other oral atypical antipsychotics: a retrospective analysis of Medicaid claims data.
Curr Med Res Opin. 2021 May;37(5):839-846. doi: 10.1080/03007995.2021.1897557. Epub 2021 Mar 23.
5
Low-Dose Lurasidone-Induced Polydipsia Complicated by Hyponatremia in a Patient With Bipolar Disorder.
Clin Neuropharmacol. 2021;44(6):243-244. doi: 10.1097/WNF.0000000000000481.
6
Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials.
BMC Psychiatry. 2016 May 23;16:157. doi: 10.1186/s12888-016-0865-y.
7
Patient Characteristics Associated With Use of Lurasidone Versus Other Atypical Antipsychotics in Patients With Bipolar Disorder: Analysis From a Claims Database in the United States.
Prim Care Companion CNS Disord. 2017 Jun 1;19(3):16m02066. doi: 10.4088/PCC.16m02066.
8
Hospitalization risk in bipolar disorder patients treated with lurasidone versus other atypical antipsychotics.
Curr Med Res Opin. 2019 Feb;35(2):211-219. doi: 10.1080/03007995.2018.1462787. Epub 2018 Apr 22.
9
The pharmacodynamic properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder.
Eur Neuropsychopharmacol. 2015 Mar;25(3):335-42. doi: 10.1016/j.euroneuro.2014.11.010. Epub 2014 Nov 29.
10
Dosing patterns and medication adherence in bipolar disorder patients treated with lurasidone: a US retrospective claims database analysis.
Ther Adv Psychopharmacol. 2016 Dec;6(6):355-368. doi: 10.1177/2045125316672135. Epub 2016 Oct 13.
引用本文的文献
1
Ethylenediaminetetraacetic acid-dependent pseudothrombocytopenia, presenting as spurious pancytopenia, associated with risperidone.
Indian J Psychiatry. 2023 Mar;65(3):386-387. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_281_22. Epub 2023 Mar 3.
本文引用的文献
1
EDTA-dependent pseudothrombocytopenia: further insights and recommendations for prevention of a clinically threatening artifact.
Clin Chem Lab Med. 2012 Aug;50(8):1281-5. doi: 10.1515/cclm-2012-0081.
2
EDTA-dependent pseudothrombocytopenia induced by valproic acid.
Neurology. 2003 Aug 26;61(4):579-80. doi: 10.1212/01.wnl.0000078229.85803.4b.
3
Olanzapine-induced EDTA-dependent pseudothrombocytopenia.
Psychosomatics. 2002 Sep-Oct;43(5):421-3. doi: 10.1176/appi.psy.43.5.421.
4
A method for estimating the probability of adverse drug reactions.
Clin Pharmacol Ther. 1981 Aug;30(2):239-45. doi: 10.1038/clpt.1981.154.
Zotero 插件